The role of radioimmunotherapy in bone marrow transplantation

Current Opinion in Hematology

Volumn 3, Issue 6, 1996, Pages 438-445

  Corcoran, Melissa C ^a   Press, Oliver W ^a   Matthews, Dana C ^b   Appelbaum, Frederick R ^b   Bernstein, Irwin D ^b  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CARMUSTINE; CD20 ANTIGEN; CD33 ANTIGEN; CD45 ANTIGEN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; ETOPOSIDE; HEMOPOIETIC GROWTH FACTOR; INDIUM 111; IODINE 131; MONOCLONAL ANTIBODY; YTTRIUM 90;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY LABELING; BONE MARROW SUPPRESSION; BONE MARROW TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; HEMATOPOIETIC STEM CELL; HODGKIN DISEASE; HUMAN; INTRAARTERIAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRATUMORAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; ISOTOPE LABELING; MYELODYSPLASIA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; RADIATION INJURY; RADIOIMMUNOTHERAPY; REVIEW; SOLID TUMOR; STEM CELL TRANSPLANTATION; WHOLE BODY RADIATION;

EID: 0029857109     PISSN: 10656251     EISSN: None     Source Type: Journal    
DOI: 10.1097/00062752-199603060-00007     Document Type: Review

References (64)

1. Travis EL, Peters LJ, McNeill J, Thames HD, Karolis C: Effect of dose-rate on total body irradiation: lethality and pathologic findings. Radiother Oncol 1985, 4:341-351.
2. Wheldon TE, O'Donoghue JA: The radiobiology of targeted radiotherapy. Int J Radiat Biol 1990, 58:1-21.
3. Langmuir VK, Sutherland RM: Radiobiology of radioimmunotherapy: current status. Antibody Immunoconjugates and Radiopharmaceuticals 1988, 1:195-211.
4. Dillehay LE, Williams JR: Radiobiological characteristics of radiolabeled immunoglobulin therapy (RIT). In Biology of Radionuclide Therapy. Edited by DeNardo GL. Washington, DC: American College of Nuclear Physicians; 1989:262-269.
5. Leibel SA, Order SE, Fisher DR, Williams JR, Morton RJ: Physics and biology of radiolabeled antibodies workshop. Antibody Immunoconjugates and Radiopharmaceuticals 1988, 1:271-282.
6. Wessels BW, Neacy WP, York ED: External beam and radiotherapy dosimetry comparison of colorectal xenografts. (Proceedings of the Fifth International Radiopharmacology Dosimetry Symposium, Oak Ridge, TN; 1991:66-76.)
7. Wessels BW, Vessella RL, Palme DF, Berkopec JM, Smith GK, Bradley EW: Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiat Oncol Biol Phys 1989, 17:1257-1263.
8. Yokota T, Milenic DE, Whitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison of other immunoglobulin forms. Cancer Res 1992, 52:3402-3408.
9. Hagan PL, Halpern SE, Dillman RO, Shawler DL, Johnson DE, Chen A, Krishnan L, Frincke J, Bartholomew RM, David GS: Tumor size: effect on monoclonal antibody uptake in tumor models. J Nucl Med 1986, 27:422-427.
10. Fujimori K, Covell DG, Fletcher JE, Weinstein JN: A modeling analysis of monoclonal antibody percolation through tumors: a binding-site barrier. J Nucl Med 1990, 31:1191-1198.
11. Buchsbaum DJ, Wahl RL, Glenn SD, Normolle DP, Kaminski MS: Improved delivery of radiolabeled anti-B1 monoclonal antibody to Rajl lymphoma xenografts by predosing with unlabeled anti-B1 monoclonal antibody. Cancer Res 1992, 52:637-642.
12. Warhoe KA, DeNardo SJ, Wolkov HB, Doggett EC, Kroger LA, Lamborn KR, DeNardo GL: Evidence for external beam irradiation enhancement of radiolabeled monoclonal antibody uptake in breast cancer. Antibody Immunoconjugates and Radiopharmaceuticals 1992, 5:227-235.
13. Msirikale JS, Klein JL, Schroeder J, Order SE: Radiation enhancement of radiolabeled antibody deposition in tumors. Int J Radiat Oncol Biol Phys 1987, 13:1839-1844.
14. Wilder RB, Langmuir VK, Mendonca HL, Goris ML, Knox SJ: Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res 1993, 53:3022-3027.
15. Leunig M, Goetz AE, Dellian M, Zetterer G, Gamorra F, Jain RK, Messmer K: Interstitial fluid pressure in solid tumors following hyperthermia: possible correlation with therapeutic response. Cancer Res 1992, 52:487-490.
16. 131I-CC49 and interferon-gamma. Dis Colon Rectum 1994, 37:s100-s105.
17. 131I-CC49) when given in combination with gamma-interferon. Cancer Res 1993, 53:600-606.
18. Nourigat C, Badger CC, Bernstein ID: Treatment of lymphoma with radiolabeled antibody: elimination of tumor cells lacking target antigen. J Natl Cancer Inst 1990, 82:47-50.
19. LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB: Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc Natl Acad Sci U S A 1989, 86:4220-4224.
20. Weiden PL, Wolf SB, Breitz HB, Appelbaum JW, Seiler CA, Mallett R, Bjom MJ, Su FM, Fer MF, Salk D: Human anti-mouse antibody suppression with cyclosporin A. Cancer 1994, 73:1093-1097.
21. 131I-labeled monoclonal antibody: analysis of retreatment following plasmapheresis. J Nucl Med 1988, 29:174-180.
22. Zimmer AM, Kazikiewicz JM, Spies WG, Goldman-Leikin R, Kaplan EH, Spies S, Webber DI, Patel BA, Rosen ST: Analysis of human antimurine mediated immunoglobulin complex formation in patients receiving murine monoclonal antibodies. Antibody Immunoconjugates and Radiopharmaceuticals 1989, 2:71-82.
23. Shawler DL, Bartholomew RM, Smith LM, Dillman RO: Human immune response to multiple injections of murine monoclonal IgG. J Immunol 1985, 135:1530-1535.
24. Schroff RW, Foon KA, Beatty SM, Oldham RK, Morgan AC: Human antimurine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res 1985, 45:879-885.
25. Kranenborg MHGC, Boerman OC, Oosterwijk-Wakka JC, deWeijert MCA, Corstens FHM, Oosterwijk E: Development and characterization of antirenal cell carcinoma x antichelate bispecific monoclonal antibodies for two-phase targeting of renal cell carcinoma. Cancer Res 1995, 55:5864s-5867s.
26. LeDoussal J-M, Barbet J, Delaage M: Bispecific-antibody-mediated targeting of radiolabeled bivalent haptens: theoretical, experimental and clinical results. Int J Cancer 1992, suppl 7:58-62.
27. Paganelli G, Pervez S, Siccardi AG, Rowlinson G, Deleide G, Chiolerio F, Malcovati M, Scassellati GA, Epenetos AA: Intraperitoneal radio-localization of tumors pro-targeted by biotinylated monoclonal antibodies. Int J Cancer 1990, 45:1184-1189.
28. Appelbaum FR, Matthews DC, Eary JF, Badger CC, Kellogg M, Press OW, Martin PJ, Fisher DR, Nelp WB, Thomas ED, Bernstein ID: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation 1992, 54:829-833.
29. 131I-labeled CD45 antibody. Toxicity of targeted radiotherapy in conjunction with cyclophosphamide and TBI as a preparative regimen was not appreciably different from standard transplant regimens.
30. 131I-anti-CD45, and allogeneic transplantation for patients with AML in first or second remission or untreated first relapse.
31. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ, Larson SM, Scheinberg DA: Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993, 11:294-303.
32. Caron PC, Schwartz MA, Co MS, Queen C, Finn RD, Graham MC, Divgi CR, Larson SM, Scheinberg DA: Murine and humanized constructs of monoclonal antibody M195 (anti-CD33) for the therapy of acute myelogenous leukemia. Cancer 1994, 73:(suppl 3):1049-1056.
33. 52Fe for additional marrow ablation before bone marrow transplantation. Blood 1993, 81:3435-3439.
34. Order SE, Porter M, Hellman S: Hodgkin's disease: evidence for a tumor associated antigen. N Engl J Med 1971, 285:471-474.
35. Eshhar Z, Order SE, Katz DH: Ferritin, a Hodgkin's disease associated antigen. Proc Natl Acad Sci U S A 1974, 71:3956-3960.
36. Lenhard RE, Order SE, Spunberg JJ, Asbell SO, Leibel SA: Isotopic immunoglobulin: a new systemic therapy for advanced Hodgkin's disease. J Clin Oncol 1985, 3:1296-1300.
37. Vriesendorp HM, Herpst JM, Germack MA, Klein JL, Leichner PK, Loudenslager DM, Order SE: Phase I-II studies of yttrium-labeled anti-ferritin treatment for end-stage Hodgkin's disease, including Radiation Therapy Oncology Group 87-01. J Clin Oncol 1991, 9:918-928.
38. 90Y-anti-ferritin. Response rate was 51%, with minimal toxicity. Responses were more frequent in patients with smaller tumors, a longer disease history, and higher blood radioactivity levels at 1 hour.
39. 90Y-anti-ferritin followed by autologous bone marrow transplantation. Significant toxicity occurred. The overall survival rate was 36%, with a progression-free survival of 21% at 12 months of follow-up.
40. Foon KA, Schroff RW, Gale RP: Surface markers on leukemia and lymphoma cells: recent advances. Blood 1982, 60:1-19.
41. Horibe K, Nadler LM: Human B cell associated antigens defined by monoclonal antibodies. In Lymphocyte Surface Antigens. Edited by Heise ER. New York: ASHI; 1984:309-324.
42. Press OW, Eary JF, Appelbaum FR, Bernstein ID: Radiolabeled antibody therapy of lymphomas. In Biologic Therapy of Cancer Updates. Edited by DeVita VT, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott Co.; 1994:1-13.
43. 2 fragments. Three patients received higher doses followed by autologous bone marrow transplantation. A 29% response rate was noted in the nonmyeloablative group. Both assessable patients in the myeloablative group attained partial responses.
44. Press OW, Eary JF, Appelbaum FR, Martin PJ, Badger CC, Nelp WB, Glenn S, Butchko G, Fisher D, Porter B, Matthews DC, Fisher LD, Bernstein ID: Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support. N Engl J Med 1993, 329:1219-1224.
45. 131I-anti-CD20 followed by autologous hematopoietic stem cell infusion. Objective responses were documented in 86% of patients (76% complete response). Toxicity was modest compared with conventional TBI-based transplantation regimens. Overall and complete response rates are superior to conventional salvage regimens for relapsed non-Hodgkin's lymphoma and comparable to those for standard bone marrow transplantation.
46. Meredith RF, Khazaeli MB, Plott WE, Saleh MN, Liu T, Allen LF, Russell CD, Orr RA, Colcher D, Schlom J, Shochat D, Wheeler RH, LoBuglio AF: Phase I trial of iodine-131-chimeric B72.3 (human IgG4) in metastatic colorectal cancer. J Nucl Med 1992, 33:23-29.
47. Wheeler RH, Meredith RF, Saleh MN, Khazaeli MB, Murray JL, LoBuglio AF: A phase II trial of IL-1 + radioimmunotherapy (RIT) in patients with metastatic colon cancer. Proc Am Soc Clin Oncol 1994, 13:295.
48. 131I-CC49 in colorectal cancer. Cancer 1994, 73:1057-1066.
49. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF: Treatment with metastatic prostate carcinoma with radiolabeled antibody CC49. J Nucl Med 1994, 35:1017-1022.
50. 131I antiferritin: an RTOG study. Int J Radiat Oncol Biol Phys 1991, 20:953-964.
51. 131I labeled monoclonal antibody (MAB) G250 in metastatic renal cell cancer (RCC). Proc Am Soc Clin Oncol 1995, 14:423.
52. 131I-3F8 targeted radiotherapy of neuroblastoma (NB): a phase I clinical trial. Proc Am Assoc Cancer Res 1990, 13:284.
53. Partridge E, Meredith R, Alvarez R, Khazaeli M, Plott G, Russell C, Schlom J, LoBuglio A: Phase I study of intraperitoneal lutetium-177 (Lu-177) monoclonal CC49 for ovarian cancer. Proc Am Assoc Cancer Res 1994, 35:505.
54. Hird V, Maraveyas A, Snook D, Dhokia B, Soutter WP, Meares C, Stewart JSW, Mason P, Lambert HE, Epenetos: Adjuvant therapy of ovarian cancer with radioactive monoclonal antibodies. Br J Cancer 1993, 68:403-406.
55. Stewart JSW, Hird V, Snook D, Sullivan M, Hooker G, Courtenay-Luck N, Sivolapenko G, Griffiths M, Myers MJ, Lambert HE, Munro AJ, Epenetos AA: Intraperitoneal radioimmunotherapy for ovarian cancer: pharmacokinetics, toxicity, and efficacy of I-131 labeled monoclonal antibodies. Int J Radiat Oncol Biol Phys 1989, 16:405-413.
56. Carrasquillo JA, Krohn KA, Beaumier P, McGuffin RW, Brown JP, Hellstrom KE, Hellstrom I, Larson SM: Diagnosis of and therapy for solid tumors with radiolabeled antibodies and immune fragments. Cancer Treat Rep 1984, 68:317-328.
57. Riva P, Marangolo M, Tison V, Moscatelli G, Franceschi G, Spinelli A, Rosti G, Morigi P, Riva N, Tirindelli D: Radioimmunotherapy trials in germ testicular carcinoma: a phase I study. Int J Biol Markers 1990, 5:188-194.
58. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res 1995, 55:5952s-5956s.
59. Hopkins K, Chandler C, Bullimore J, Sandeman D, Coakham H, Kemshead JT: A pilot study of the treatment of patients with recurrent malignant gliomas with intratumoral yttrium-90 radioimmunoconjugates. Radiother Oncol 1995, 34:121-131.
60. 125I labeled monoclonal antibody against epidermal growth factor receptor. Antibody Immunoconjugates and Radiopharmaceuticals 1990, 3:169-179.
61. DeNardo SJ, O'Grady LF, Richman CM, DeNardo GL: Overview of radioimmunotherapy in advanced breast cancer using I-131 chimeric L6. In Antigen and Antibody Molecular Engineering in Breast Cancer Diagnosis and Treatment. Edited by Ceriani RL. New York: Plenum Press; 1994:203-211.
62. 131I-labeled chimeric L6. The administration of three fractions was only permissible in the third patient, who received cyclosporine and thus did not form human antimouse antibodies. This study provides insight that repetitive myeloablative doses of radiolabeled antibody followed by peripheral blood stem rescue may translate into improved clinical efficacy for treating solid tumors.
63. 131I chimeric (Ch) L6 with peripheral blood stem cell (PBSC) support and cyclosporin (CSA). Proc Am Soc Clin Oncol 1995, 14:322.
64. 90Y in bone (disassociation of radiolabel from the chelating molecule) was in part responsible for myelosuppression. Dose-limiting toxicity has not been met, but will likely be hepatic or pulmonary in nature, given dosimetry studies.